CTOs on the Move

BioSig Technologies

www.biosigtech.com

 
BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.biosigtech.com
  • 8441 Wayzata Blvd Ste 240
    Minneapolis, MN USA 55426
  • Phone: 763.999.7330

Executives

Name Title Contact Details

Similar Companies

Avamere

Avamere Family of Companies, a group of independent privately owned post-acute care companies, is dedicated to seniors` health and well-being. We take great pride in offering a continuum of care, which allows seniors to stay independent and active.

Takeda San Diego

Takeda San Diego is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lawndale Christian Health Center

Lawndale Christian Health Center is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NovaSom

NovaSom is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Histogenics

Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics` regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics` first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.